Journal Mobile Options
Table of Contents
Vol. 13, No. 4, 2007
Issue release date: September 2007

A System for the Random Mutagenesis of the Two-Peptide Lantibiotic Lacticin 3147: Analysis of Mutants Producing Reduced Antibacterial Activities

Field D. · Collins B. · Cotter P.D. · Hill C. · Ross R.P.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Lantibiotics are antimicrobial peptides that contain several unusual amino acids resulting from a series of enzyme-mediated posttranslational modifications. As a consequence of being gene-encoded, the implementation of peptide bioengineering systems has the potential to yield lantibiotic variants with enhanced chemical and physical properties. Here we describe a functional two-plasmid expression system which has been developed to allow random mutagenesis of the two-component lantibiotic, lacticin 3147. One of these plasmids contains a randomly mutated version of the two structural genes, ltnA1 and ltnA2, and the associated promoter, Pbac, while the other encodes the remainder of the proteins required for the biosynthesis of, and immunity to, lacticin 3147. To test this system, a bank of ∼1,500 mutant strains was generated and screened to identify mutations that have a detrimental impact on the bioactivity of lacticin 3147. This strategy established/confirmed the importance of specific residues in the structural peptides and their associated leaders and revealed that a number of alterations which mapped to the –10 or –35 regions of Pbac abolished promoter activity.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Cotter PD, Hill C, Ross RP: Food microbiology: bacteriocins: developing innate immunity for food. Nat Rev Microbiol 2005;3:777–788.
  2. Chatterjee C, Paul M, Xie L, van der Donk WA: Biosynthesis and mode of action of lantibiotics. Chem Rev 2005;105:633–684.
  3. Guder A, Wiedemann I, Sahl HG: Posttranslationally modified bacteriocins – the lantibiotics. Biopolymers 2000;55:62–73.
  4. Galvin M, Hill C, Ross RP: Lacticin 3147 displays activity in buffer against Gram-positive bacterial pathogens which appear insensitive in standard plate assays. Lett Appl Microbiol 1999;28:355–358.
  5. Ryan MP, Rea MC, Hill C, Ross RP: An application in cheddar cheese manufacture for a strain of Lactococcus lactis producing a novel broad-spectrum bacteriocin, lacticin 3147. Appl Environ Microbiol 1996;62:612–619.
  6. McAuliffe O, Ryan MP, Ross RP, Hill C, Breeuwer P, Abee T: Lacticin 3147, a broad-spectrum bacteriocin which selectively dissipates the membrane potential. Appl Environ Microbiol 1998;64:439–445.
  7. Morgan SM, O’Connor PM, Cotter PD, Ross RP, Hill C: Sequential actions of the two component peptides of the lantibiotic lacticin 3147 explain its antimicrobial activity at nanomolar concentrations. Antimicrob Agents Chemother 2005;49:2606–2611.
  8. Wiedemann I, Bottiger T, Bonelli RR, Wiese A, Hagge SO, Gutsmann T, Seydel U, Deegan L, Hill C, Ross P, Sahl HG: The mode of action of the lantibiotic lacticin 3147 – a complex mechanism involving specific interaction of two peptides and the cell wall precursor lipid II. Mol Microbiol 2006;61:285–296.
  9. Cotter PD, O’ Connor PM, Draper LA, Lawton EM, Deegan LH, Hill C, Ross RP: Post-translational conversion of L-serines to D-alanines is vital for optimal production and activity of the lantibiotic Lacticin 3147. Proc Natl Acad Sci USA 2005;102:18584–18589.
  10. Martin NI, Sprules T, Carpenter MR, Cotter PD, Hill C, Ross RP, Vederas JC: Structural characterization of lacticin 3147, a two-peptide lantibiotic with synergistic activity. Biochemistry 2004;43:3049–3056.
  11. Ryan MP, Jack RW, Josten M, Sahl HG, Jung G, Ross RP, Hill C: Extensive post-translational modification, including serine to D-alanine conversion, in the two-component lantibiotic, lacticin 3147. J Biol Chem 1999;274:37544–37550.
  12. Kawai Y, Ishii Y, Arakawa K, Uemura K, Saitoh B, Nishimura J, Kitazawa H, Yamazaki Y, Tateno Y, Itoh T, Saito T: Structural and functional differences in two cyclic bacteriocins with the same sequences produced by lactobacilli. Appl Environ Microbiol 2004;70:2906–2911.
  13. Skaugen M, Nissen-Meyer J, Jung G, Stevanovic S, Sletten K, Inger C, Abildgaard M, Nes IF: In vivo conversion of L-serine to D-alanine in a ribosomally synthesized polypeptide. J Biol Chem 1994;269:27183–27185.
  14. Breukink E, de Kruijff B: Lipid II as a target for antibiotics. Nat Rev Drug Discov 2006;5:321–332.
  15. Cotter PD, Deegan L, Lawton EM, Draper LA, O’Connor PM, Hill C, Ross RP: Complete alanine scanning of the two-component lantibiotic lacticin 3147: generating a blueprint for rational drug design. Mol Microbiol 2006;62:735–747.
  16. Dodd HM, Hao Z, Horn N, Gasson MJ: A Lactococcal expression system for engineered nisins. Appl Environ Microbiol 1992;58:3683–3693.
  17. Kuipers OP, Beerthuyzen MM, Siezen R, De Vos WM: Characterization of the nisin gene cluster nisABTCIPR of Lactococcus lactis. Requirement of expression of the nisA and nisI genes for development of immunity. Eur J Biochem 1993;216:281–291.
  18. Kuipers OP, Rollema HS, Yap WMGJ, Boot HJ, Seizen RJ, de Vos WM: Engineering dehydrated amino acids residues in the antimicrobial peptide nisin. J Biol Chem 1992;267:24340–24346.
  19. Liu W, Hansen JN: Enhancement of the chemical and antimicrobial properties of subtilin by site-directed mutagenesis. J Biol Chem 1992;267:25078–25085.
  20. Bierbaum G, Reis M, Szekat C, Sahl HG: Construction of an expression system for engineering of the lantibiotic Pep5. Appl Environ Microbiol 1994;60:4332–4338.
  21. Chen P, Novak J, Kirk M, Barnes S, Qi F, Caufield PW: Structure-activity study of the lantibiotic mutacin II from Streptococcus mutans T8 by a gene replacement strategy. Appl Environ Microbiol 1998;64:2335–2340.
  22. Szekat C, Jack RW, Skutlarek D, Farber H, Bierbaum G: Construction of an expression system for site-directed mutagenesis of the lantibiotic mersacidin. Appl Environ Microbiol 2003;69:3777–3783.
  23. Widdick DA, Dodd HM, Barraille P, White J, Stein TH, Chater KF, Gasson MJ, Bibb MJ: Cloning and engineering of the cinnamycin biosynthetic gene cluster from Streptomyces cinnamoneus cinnamoneus DSM 40005. Proc Natl Acad Sci USA 2003;100:4316–4321.
  24. O’Driscoll J, Glynn F, Cahalane O, O’Connell-Motherway M, Fitzgerald GF, van Sinderen D: Lactococcal plasmid pNP40 encodes a novel, temperature-sensitive restriction-modification system. Appl Environ Microbiol 2004;70:5546–5556.
  25. Cotter PD, Draper LA, Lawton EM, McAuliffe O, Hill C, Ross RP: Overproduction of wild-type and bioengineered derivatives of the lantibiotic lacticin 3147. Appl Environ Microbiol 2006;72:4492–4496.
  26. Jensen PR, Hammer K: Artificial promoters for metabolic optimization. Biotechnol Bioeng 1998;58:191–195.
  27. McAuliffe O, O’Keeffe T, Hill C, Ross RP: Regulation of immunity to the two-component lantibiotic, lacticin 3147, by the transcriptional repressor LtnR. Mol Microbiol 2001;39:982–993.
  28. Ottenwalder B, Kupke T, Brecht S, Gnau V, Metzger J, Jung G, Gotz F: Isolation and characterization of genetically engineered gallidermin and epidermin analogs. Appl Environ Microbiol 1995;61:3894–3903.
  29. Navaratna MA, Sahl HG, Tagg JR: Identification of genes encoding two-component lantibiotic production in Staphylococcus aureus C55 and other phage group II S. aureus strains and demonstration of an association with the exfoliative toxin B gene. Infect Immun 1999;67:4268–4271.
  30. Holo H, Jeknic Z, Daeschel M, Stevanovic S, Nes IF: Plantaricin W from Lactobacillus plantarum belongs to a new family of two-peptide lantibiotics. Microbiology 2001;147:643–651.
  31. Van der Meer JR, Rollema HS, Siezen RJ, Beerthuyzen MM, Kuipers OP, de Vos WM: Influence of amino acid substitutions in the nisin leader peptide on biosynthesis and secretion of nisin by Lactococcus lactis. J Biol Chem 1994;269:3555–3562.
  32. Neis S, Bierbaum G, Josten M, Pag U, Kempter C, Jung G, Sahl HG: Effect of leader peptide mutations on biosynthesis of the lantibiotic Pep5. FEMS Microbiol Lett 1997;149:249–255.
  33. Chen P, Qi FX, Novak J, Krull RE, Caufield PW: Effect of amino acid substitutions in conserved residues in the leader peptide on biosynthesis of the lantibiotic mutacin II. FEMS Microbiol Lett 2001;195:139–144.
  34. Brouns SJJ, Wu H, Akerboom J, Turnbull AP, De Vos WM, van der Oost J: Engineering a selectable marker for hyperthermophiles. J Biol Chem 2005;280:11422–11431.
  35. Delmas J, Robin F, Carvalho F, Mongaret C, Bonnet R: Prediction and evolution of ceftazidime resistance in extended-spectrum β-lactamase CTX-M-9. Antimicrob Agents Chemother 2006;50:731–738.
  36. Wurth C, Guimard NK, Hecht MH: Mutations that reduce aggregation of the Alzheimer’s Aβ42 peptide: an unbiased search for the sequence determinants of Aβ amyloidogenesis. J Mol Biol 2002;319:1279–1290.
  37. Pag U, Sahl HG: Multiple activities in lantibiotics – models for the design of novel antibiotics? Curr Pharm Des 2002;8:815–833.
  38. Yuan J, Zhang ZZ, Chen XZ, Yang W, Huan LD: Site-directed mutagenesis of the hinge region of nisinZ and properties of nisinZ mutants. Appl Microbiol Biotechnol 2004;64:806–815.
  39. Rollema HS, Kuipers OP, Both P, de Vos WM, Siezen RJ: Improvement of solubility and stability of the antimicrobial peptide nisin by protein engineering. Appl Environ Microbiol 1995;61:2873–2878.
  40. Poirot O, O’Toole E, Notredame C: Tcoffee@igs: a web server for computing, evaluating and combining multiple sequence alignments. Nucleic Acids Res 2003;31:3503–3506.
  41. Coakley M, Fitzgerald G, Ros RP: Application and evaluation of the phage resistance- and bacteriocin-encoding plasmid pMRC01 for the improvement of dairy starter cultures. Appl Environ Microbiol 1997;63:1434–1440.
  42. Cotter PD, Hill C, Ross RP: A food-grade approach for functional analysis and modification of native plasmids in Lactococcus lactis. Appl Environ Microbiol 2003;69:702–706.
  43. Hayes F, Daly C, Fitzgerald GF: Identification of the minimal replicon of Lactococcus lactis subsp. lactis UC317 plasmid pCI305. Appl Environ Microbiol 1990;56:202–209.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50